EU regulator backs Roche's faster-acting lymphoma drug in injectable form

Follicular lymphoma affects over 110,000 people annually worldwide; this treatment offers improved quality of life through reduced administration burden for relapsed or refractory patients.

In the long struggle against cancers that return and resist, medicine occasionally finds not just a new weapon but a more humane way to wield it. European regulators have recommended approval of a subcutaneous form of Roche's Lunsumio — a bispecific antibody that recruits the body's own immune cells to destroy follicular lymphoma — reducing treatment from hours of intravenous infusion to a single minute's injection. For the more than 110,000 people diagnosed with this relentless disease each year, and especially those for whom earlier treatments have already failed, the recommendation signals

EU regulator backs Roche's faster-acting lymphoma drug in injectable form

Cobertura Relacionada

Recibe The Register en tu bandeja